Mesothelioma Cancer Centers
UCHealth Lung Cancer Clinic – Anschutz Medical Campus
Doctors Affiliated with this Treatment Facility
The University of Colorado School of Medicine’s history dates back to 1883, when the university created its Department of Medicine and Surgery on its Boulder campus. For the next several decades, students shuffled between Boulder and Denver for their classes, but in 1911 the School of Medicine merged with the Denver and Gross Medical College, opening the doors for the school’s permanent move to Denver in 1925. That hospital site would later become the University of Colorado Health Sciences Center.
The medical center continued to grow throughout the 20th century: In 1947, the hospital was allowed to take responsibility for patients referred from Denver General Hospital. In the 1990s, hospital officials asked the U.S. Department of Defense for permission to repurpose the closed Fitzsimons Army Medical Center as an academic health center. The defense department agreed, and the first university labs moved to the Fitzsimons research towers in 2004. Shortly thereafter, the Fitzsimons campus was renamed the Anschutz Medical Campus in recognition of donations from Philip and Nancy Anschutz.
The university’s board voted to rename the campus as the University of Colorado Denver in 2007, the same year it opened a new $644 million, 820,000-square-foot facility. Today the University of Colorado Hospital is affiliated with Children’s Hospital Colorado, Denver Health, National Jewish Health and the Veterans Affairs Medical Center.
The University of Colorado (CU) Cancer Center, located on the CU Anschutz Medical Campus, features a Peritoneal Cancer Multidisciplinary Clinic. The clinic treats cancers of the peritoneal (abdominal) cavity, including mesothelioma. Operating as a clinic allows patients to receive care from multiple disciplines including surgery, medical oncology, pathology, radiology and nutritionists. Using the expertise from all these departments enables a patient's care team to approach their cancer with a multimodal treatment plan using numerous therapies. The members of the care team meet all together in one day and create a treatment plan by the end of the visit. Such quick action improves patient outcomes by fast tracking treatment.
The experience of the facility, and the specialists employed there, further contribute to improved patient outcomes. The surgeons at the Peritoneal Cancer Multidisciplinary Clinic have performed more than 500 cytoreductive surgery/heated intraperitoneal chemotherapy (CRS/HIPEC) procedures. They have found that this combination of treatment leads to an improved survival and greater quality of life for patients with peritoneal malignancies, like peritoneal mesothelioma.
Patients treated at the University of Colorado Cancer Center benefit from the center’s more than $75 million in annual cancer research funding and the wide variety of clinical trials offered. Almost 20% of patients diagnosed at the University of Colorado Cancer Center are enrolled in clinical trials. These trials, and the overall multimodal approach to cancer care, have helped the Cancer Center achieve the best 5-year survival rates of any center in the Rocky Mountain region.
- Cytoreductive surgery
- Heated intraperitoneal chemotherapy (HIPEC)
- Intraperitoneal chemotherapy
- Peritoneal mesothelioma
- Systemic chemotherapy
- Employs doctors that are on the National Comprehensive Cancer Network advisory panel
- Member of the Oncology Research Information Exchange Network (ORIEN)
- National Cancer Institute Designated Comprehensive Cancer Center (National Cancer Institute (NCI) designation)
- U.S. News & World Report’s Top Hospital in Colorado
Mesothelioma Clinical Trials at UCHealth Lung Cancer Clinic – Anschutz Medical Campus
The following clinical trials are in progress or actively recruiting participants at UCHealth Lung Cancer Clinic – Anschutz Medical Campus:
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortex Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Cervical Adenocarcinoma; Cervical Clear Cell Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid-Type Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Carcinoid Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Testicular Sex Cord-Stromal Tumor; Metaplastic Breast Carcinoma; Metastatic Malignant Neoplasm of Unknown Primary; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Clear Cell Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Peritoneal Mesothelioma; Pituitary Gland Carcinoma; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Solid Neoplasm; Spindle Cell Neoplasm; Squamous Cell Carcinoma of the Penis; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma Last Updated: July 18, 2019 Status: Recruiting
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Conditions: Mesothelin Positive; Pleural Malignant Mesothelioma Last Updated: July 17, 2019 Status: Recruiting
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Conditions: Solid Tumors; Malignant Pleural Mesothelioma; Gastric Adenocarcinoma; Colorectal Adenocarcinoma; Sarcoma Last Updated: July 17, 2019 Status: Recruiting
Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
Conditions: Mesothelioma; Pleural Mesothelioma Last Updated: June 17, 2019 Status: Active, not recruiting
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
Conditions: Advanced Malignant Solid Neoplasm; Advanced Peritoneal Malignant Mesothelioma; Advanced Pleural Malignant Mesothelioma; Recurrent Peritoneal Malignant Mesothelioma; Recurrent Pleural Malignant Mesothelioma; Refractory Malignant Solid Neoplasm; Unresectable Solid Neoplasm Last Updated: June 10, 2019 Status: Recruiting
Author: Linda Molinari
Editor in Chief, Mesothelioma Cancer AllianceRead about Linda
Reviewer: Annette Charlevois
Patient Support CoordinatorRead about Annette
University of Colorado Anschutz Medical Campus. CU Anschutz Medical Campus. Where we Are.
University of Colorado Anschutz Medical Campus Department of Surgery. Peritoneal Cancer Multidisciplinary Clinic. Multidisciplinary Care.
University of Colorado Cancer Center. Facts, Figures & History. About Us.
University of Colorado Cancer Center. Why Chose Us? Cancer Care.